Regulatory perspective on remaining challenges for utilization of pharmacogenomics-guided drug developments.

Yasuto Otsubo,Akihiro Ishiguro,Y. Uyama
DOI: https://doi.org/10.2217/pgs.12.194
2013-01-17
Abstract:Pharmacogenomics-guided drug development has been implemented in practice in the last decade, resulting in increased labeling of drugs with pharmacogenomic information. However, there are still many challenges remaining in utilizing this process. Here, we describe such remaining challenges from the regulatory perspective, specifically focusing on sample collection, biomarker qualification, ethnic factors, codevelopment of companion diagnostics and means to provide drugs for off-target patients. To improve the situation, it is important to strengthen international harmonization and collaboration among academia, industries and regulatory agencies, followed by the establishment of an international guideline on this topic. Communication with a regulatory agency from an early stage of drug development is also a key to success.
What problem does this paper attempt to address?